Setting realistic weight loss expectations with Wegovy

Why trial averages are only part of the picture

An average of 15% sounds precise, but averages hide a spread. In STEP 1, some participants lost closer to 5% of their starting weight; others lost 20% or more. The number that lands on a headline is the midpoint of a wide distribution, not a promise that applies to you specifically.

Several things push results higher or lower. How consistently you take each weekly dose matters. So does whether your diet and activity genuinely change alongside the injection. Starting weight plays a role, as does how long you stay on treatment and how your body tolerates the titration schedule (the gradual dose increases from 0.25 mg up to the standard 2.4 mg maintenance dose, each step roughly four weeks apart under your prescriber's guidance).

Genetics and metabolic history also have an effect that no trial figure can pre-calculate for an individual. Some people notice a dramatic shift in appetite within the first few weeks; others find the change more gradual. Both experiences can lead to meaningful weight loss over the full treatment period, and our dedicated guide to weight loss on Wegovy explores what drives those individual differences in more depth. What happens in the first week is often quite different from what happens by month six, and that trajectory matters more than any single weigh-in.

The honest framing, then, is this: the evidence gives you a credible range, not a figure to bank on. Your prescriber's job is to help you understand where you might reasonably land and what to watch for along the way.

The 7.2 mg dose changes the expectation ceiling

For a long time, the conversation about Wegovy expectations was anchored to the 2.4 mg dose. That changed in January 2026 when the MHRA approved a higher 7.2 mg maintenance dose, and again in April 2026 when a dedicated single-dose 7.2 mg pen received approval. Trial data for this higher dose reported roughly 20.7% average weight loss over 72 weeks, a meaningful step up from the 15% benchmark most people associate with semaglutide.

This matters for setting expectations because it means the ceiling for Wegovy-based treatment is now higher than it was two years ago. The starting dose remains 0.25 mg regardless of which maintenance dose you ultimately reach, and the titration journey is the same careful, step-by-step process. Whether the 7.2 mg dose is appropriate for you is a clinical decision, not a consumer one. Detailed evidence on what Wegovy users typically lose covers the dose-by-dose breakdown in more depth.

It is also worth noting that the 7.2 mg pen is licensed for adults with a BMI of 30 or above (not for lower BMI thresholds) and specific dose and pen availability is confirmed at the time of your consultation rather than assumed in advance.

The six-month checkpoint, and what NICE says about it

One of the most practically useful pieces of guidance for anyone thinking about Wegovy weight loss expectations comes from NICE's appraisal of semaglutide (TA875). It recommends that treatment should be reviewed if weight loss has not reached at least 5% of starting body weight after six months on the maintenance dose. That is not a punishment clause; it is a clinical safeguard designed to identify early whether the treatment is working sufficiently for a given individual.

What this means in practice: the first few months on a low titration dose are not the right moment to judge results. Nausea, adjustment, and the slow climb up the dosing schedule mean that early weeks rarely reflect long-term outcomes. How long Wegovy takes to work depends partly on how quickly you tolerate each dose step, which varies from person to person.

If you want a rough sense of what a month-by-month trajectory might look like, the month-by-month breakdown of Wegovy weight loss is a useful reference. The early months are typically slower; loss tends to accelerate once maintenance doses are reached. Setting your expectations around the full 68-week picture, rather than the first four weeks, leads to a more accurate read of how treatment is going.

Our prescribers review progress at each repeat order, every prescription at nume is clinically re-assessed, so questions about whether your trajectory looks right for you have a natural place to be raised. If you are considering starting treatment, checking your eligibility through a free consultation is the first step.

Lifestyle, stopping, and the longer view

Wegovy is not a standalone intervention. The clinical trials that generated the 15% and 20.7% figures were conducted alongside a reduced-calorie diet and increased physical activity. Participants were also given structured behavioural support in a trial setting. Real-world results in people who change nothing else about their eating or movement tend to be lower.

The other part of expectations worth addressing honestly: what happens when treatment stops. Weight regain after discontinuing GLP-1 medicines is well documented. This does not mean treatment has failed, it reflects the biology of appetite regulation, not a personal shortcoming. For many people, this points towards treating weight management as an ongoing clinical relationship rather than a fixed-term course. NICE recommends semaglutide for a maximum of two years when prescribed within a specialist service on the NHS; private prescribing timelines are discussed with your prescriber.

For a fuller picture of the treatment itself before thinking through these decisions, the main Wegovy overview covers how the medicine works, who it is licensed for, and how the NHS and private routes compare. And if you are still deciding between available options, comparing the licensed weight-loss treatments available in the UK is a reasonable next step before a consultation.